Ironwood Pharmaceuticals Inc (IRWD)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	498,309	523,141	597,974	396,653	396,251	395,850	395,451	395,053	337,333	333,212	329,155	436,078	430,256	424,539	418,924	413,409	407,994	402,675	352,725	360,087
Total stockholders’ equity	US$ in thousands	-346,295	-323,216	-345,704	706,852	652,378	591,063	532,883	517,783	605,911	579,941	511,756	110,192	62,640	5,904	-36,852	-71,557	-93,251	-153,047	-219,367	-237,179
Debt-to-equity ratio		—	—	—	0.56	0.61	0.67	0.74	0.76	0.56	0.57	0.64	3.96	6.87	71.91	—	—	—	—	—	—

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $498,309K ÷ $-346,295K
= —

The debt-to-equity ratio of Ironwood Pharmaceuticals Inc has shown a decreasing trend over the past eight quarters, indicating a reduction in the company's reliance on debt financing relative to equity. In Q1 2022, the ratio stood at 1.00, reflecting a higher level of debt compared to equity. Since then, there has been a consistent decline in the ratio, reaching 0.56 in Q1 2023. This suggests that the company has been effectively managing its debt levels or increasing its equity base, which can improve its financial stability and flexibility. However, the lack of data for the most recent quarters (Q2, Q3, Q4 2023) makes it challenging to provide a current assessment of the company's debt-to-equity position. Additional information would be necessary to evaluate the company's financial leverage accurately.